Larkspur Biosciences
Catherine Sabatos-Peyton has over 20 years of experience in the biotechnology and pharmaceutical industries, with expertise in immunotherapy, immune modulation, and molecular biology. Catherine currently serves as the Chief Executive Officer at Larkspur Biosciences, which develops precision immunotherapies for molecularly defined patient populations. Prior to this, they had roles as Chief Scientific Officer at a biotech company in stealth mode, Executive Director and Head of Immune Modulation at Novartis Institutes for BioMedical Research (NIBR), and as Senior Investigator at Novartis. Catherine also served as Director of Immunology at CoStim Pharmaceuticals and as a Research Fellow at the University of Bristol. Sabatos-Peyton received their PhD from Harvard Medical School and completed postdoctoral work at UCSF.
Catherine Sabatos-Peyton obtained their Bachelor's degree in Biology from Fordham University, completing their studies between 1992 to 1996. Afterwards, they pursued their PhD in Immunology from Harvard University during the years 1997 to 2004. No information was given about their degree or field of study at the University of Oxford.
This person is not in any teams
Larkspur Biosciences
Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.